Safety and tolerance profile of venlafaxine

International Clinical Psychopharmacology

Volumn 10, Issue , 1995, Pages 15-20

  Danjou, P ^a   Hackett, D ^a  

^a Wyeth Ayerst Clin Res and D   (France)

Author keywords

Clinical pharmacology; Elderly patients; Safety; Tolerability; Venlafaxine

Indexed keywords

AMINEPTINE; CLOMIPRAMINE; DOSULEPIN; IMIPRAMINE; MAPROTILINE; TRAZODONE; VENLAFAXINE; ANTIDEPRESSANT AGENT; ANTIDEPRESSIVE AGENTS, SECOND GENERATION; CYCLOHEXANOL DERIVATIVE;

AGING; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG COMPARISON; DRUG SAFETY; DRUG TOLERANCE; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; XEROSTOMIA; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG TOLERANCE; HUMAN;

EID: 0028987470     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/00004850-199503002-00004     Document Type: Article

References (7)

1. Crewe HK, Lennard MS., Tucker GT, Woods FR and Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34. 262-265.
2. Minot R, Luthringer R, Toussaint M., Schattenbrand N., Granier LA., Magni G and Macher JP (1992) Neurophysical, longitudinal, placebo controlled study of venlafaxine in depressed inpatients. Clinical Neuropharmacology, 15 (Suppl 1, Part B). 322B.
3. Muth EA, Haskins JT, Moyer JA., Husbands GEM, Nielsen ST and Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45.030, an ethyl cyclohexano! derivative. Biochemical Pharmacology, 35. 4493-4497.
4. Muth EA, Moyer JA., Haskins JT., Andree TH and Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research, 23, 191-199.
5. Parker V, Paerg L, Maloney K, Rudolph R., Derivan A and Chiang S (1990) Effect of age and sex on the pharmacokinetics of venlafaxine. Journal of Clinical Pharmacology, 30. 832.
6. Saletu B, Grünberger J., Anderer P., Linzmayer L, Semlitseh HV and Magni G (1992) Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. British Journal of Clinical Pharmacology. 33, 589-6.
7. Wang CP., Howell SR, Scatine J and Sisenwine SF (1992) The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality, 4. 84-90.